Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol

Acta Psychiatrica Scandinavica

Volumn 97, Issue 6, 1998, Pages 458-466

  Galinowski, A ^a   Poirier, M F ^a   Aymard, N ^a,b   Leyris, A ^a   Beauverie, P ^a   Bourdel, M C ^a   Loo, H ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Haloperidol; Homovanillic acid; Prognosis; Schizophrenia

Indexed keywords

HALOPERIDOL; HOMOVANILLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONJUGATION; DEAMINATION; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; MALE; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031812326     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1998.tb10031.x     Document Type: Article

References (34)

1. BACOPOULOS NG, HATTOX SE, ROTH R. 3, 4 Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacology 1979: 56: 225-236.
2. LIEBERMAN JA, KOREEN A. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993: 19: 371-429.
3. MAAS JW, CONTRERAS SA, MILLER AL et al. Studies of catecholamine metabolism in schizophrenia/psychosis. I. Neuropsychopharmacology 1993: 8: 97-109.
4. MAAS JW, CONTRERAS SA, MILLER AL et al. Studies of catecholamine metabolism in schizophrenia/psychosis. II. Neuropsychopharmacology 1993: 8: 111-116.
5. SHARMA R, JAVAID JI, JANICAK P, FAULL K, COMATY J, DAVIS JM. Plasma and CSF HVA before and after pharmacological treatment. Psychiatr Res 1989: 28: 97-104.
6. KOREEN AR, LIEBERMAN J, ALVIR J et al. Plasma homovanillic acid levels in first-episode schizophrenia. Arch Gen Psychiatry 1994: 51: 132-138.
7. WEI J, XU HM, HEMMINGS GP. Studies on neurochemical heterogeneity in healthy parents of schizophrenic patients. Schizophr Res 1993: 10: 173-178.
8. DAVILA R, MANERO E, ZUMARRAGA M, ANDIA I, SCHWEITZER J, FRIEDHOFF AJ. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 1988: 45: 564-567.
9. SHARMA RP, JAVAID JI, JANICAK PG, DAVIS JM, FAULL K. Homovanillic acid in cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment. Biol Psychiatry 1993: 34: 128-134.
10. DUNCAN E, WOLKIN A, ANGRIST B et al. Plasma homovanillic acid in neuroleptic responsive and non-responsive schizophrenics. Biol Psychiatry 1993: 34: 523-528.
11. RIVETT AJ, EDDY BJ, ROTH JA. Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain. J Neurochem 1982: 39: 1009-1016.
12. LAUNAY JM, SOLIMAN H, PRADALIER A, CAUET N, DREUX C, DRY J. Non-dietary common migraine: biochemical evidence for the existence of plasma releasing factors. In: CLIFFORD ROSE F, ed. New advances in headache research. London: Smith Gordon, 1989: 79-84.
13. KUCHEL O, NGUYEN T.B, HAMET P, LAROCHELLE P, BOURQUE M, GENEST J. Catecholamine sulfates and platelet phenolsulfotransferase activity in essential hypertension. J Lab Clin Med 1984: 104: 238-244.
14. GARCIA A, GALINOWSKI A, GUICHENEY P, MIGNOT E, LOO H, MEYER P. Free and conjugated plasma homovanillic acid in schizophrenic patients. Biol Psychiatry 1989: 26: 87-96.
15. OVERALL JE, GORHAM DE. The Brief Psychiatric Rating Scale. Psychol Rep 1962: 10: 799-812.
16. ASBERG M, MONTGOMERY SA, PERRYS C, SCHALLING D, SEDVALL G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978: Suppl. 271: 5-27.
17. GUY W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare, 1976.
18. JATLOW PI, MILLER R, SWIGAR M. Measurement of haloperidol in human plasma using reversed-phase high performance liquid chromatography. J Chromatography 1982: 227: 233-238.
19. 2 dopamine receptor occupancy by PET. Psychopharmacology 1988: 94: 1-7.
20. MIGNOT E, GARCIA A, LAUDE D et al. Value of plasma HVA level in humans: influence of renal function, food intake and psychiatric state. Biogenic Amines 1988: 5: 169-176.
21. NEWCOMER JW, RINEY SJ, VINOGRADOV S, CSERNANSKY JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. Psychiatr Res 1992: 41: 191-202.
22. SUZUKI E, KANBA S, NIBUYA M et al. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated patients. Biol Psychiatry 1994: 36: 654-661.
23. CONTRERAS S, MAAS J, SELESHI E, BOWDEN C. Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics. Biol Psychiatry 1988: 24: 815-818.
24. MILLER AL, MAAS JW, CONTRERAS S et al. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiatry 1993: 34: 178-187.
25. MAGLIOZZI JR, DORAN AR, GIETZEN DW, OLSON AM, MACLIN EL, TUASON VB. Effects of single-dose haloperidol administration on plasma homovanillic acid levels in normal subjects. Psychiatr Res 1993: 47: 141-149.
26. DAVILA R, ZUMARRAGA M, PEREA K, ANDIA I, FRIEDHOFF AJ. Elevation of plasma homovanillic acid can be detected within four hours after initiation of haloperidol treatment. Arch Gen Psychiatry 1987: 44: 837-838.
27. DAVIDSON M, GIORDANI AB, MOHS RC et al. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentrations. Arch Gen Psychiatry 1987: 44: 89-190.
28. GRACE A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991: 41: 1-24.
29. DAVILA R, ZUMARRAGA M, ANDIA I, FRIEDHOFF AJ. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic-treated schizophrenic patients. Life Sci 1989: 44: 1117-1121.
30. RIBEYRE JM, LESIEUR P, VAROQUAUX O, DOLLFUS S, PAYS M, PETIT M. A comparison of plasma homovanillic acid in the deficit and non-deficit subtypes of schizophrenia. Biol Psychiatry 1994: 36: 230-236.
31. DORAN AR, LABARCA R, WOLKOWITZ OM, ROY A, DOUILLET P, PICKAR D. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. Arch Gen Psychiatry 1990: 47: 558-563.
32. DAVIDSON M, KAHN RS, STERN RS et al. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatr Res 1993: 46: 151-153.
33. VAN PUTTEN T, MAY PRA, JENDEN DJ. Does a plasma level of chlorpromazine help? Psychol Med 1981: 11: 729-734.
34. KANE JM, HONIGFELD G, SINGER J, MELTZER HY. Clozapine for the treatment-resistant schizophrenics. Arch Gen Psychiatry 1988: 45: 789-796.